|

GD2 CAR T cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • University College, London1

Indications

  • Neuroblastoma1
  • Cancer1

Other1 trial

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.